000062862 001__ 62862
000062862 005__ 20200402210514.0
000062862 0247_ $$2pmid$$apmid:18328004
000062862 0247_ $$2DOI$$a10.1089/rej.2008.0670
000062862 0247_ $$2WOS$$aWOS:000255773200008
000062862 0247_ $$2altmetric$$aaltmetric:21819147
000062862 037__ $$aPreJuSER-62862
000062862 041__ $$aeng
000062862 082__ $$a610
000062862 084__ $$2WoS$$aGeriatrics & Gerontology
000062862 1001_ $$0P:(DE-Juel1)VDB65869$$aFunke, S. A.$$b0$$uFZJ
000062862 245__ $$aAn Ultra-Sensitive Assay For Diagnosis Of Alzheimer's Disease
000062862 260__ $$aLarchmont, NY$$bLiebert$$c2008
000062862 300__ $$a315 - 318
000062862 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000062862 3367_ $$2DataCite$$aOutput Types/Journal article
000062862 3367_ $$00$$2EndNote$$aJournal Article
000062862 3367_ $$2BibTeX$$aARTICLE
000062862 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000062862 3367_ $$2DRIVER$$aarticle
000062862 440_0 $$018202$$aRejuvenation Research$$v11$$x1549-1684$$y2
000062862 500__ $$aRecord converted from VDB: 12.11.2012
000062862 520__ $$aAlzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia. Aging is among the most significant risk factors. Today, AD can be diagnosed with certainty only post mortem, detecting insoluble beta-amyloid peptide (Abeta) aggregates in the patient's brain tissue. We have developed an ultrasensitive assay for early and non-invasive diagnosis of AD. This highly specific and sensitive assay uses fluorescence correlation spectroscopy (FCS) and is sensitive enough to detect even single aggregates in body fluids of AD patients. We investigate the correlation of aggregated Abeta concentrations in body fluids with clinical symptoms of AD.
000062862 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000062862 588__ $$aDataset connected to Web of Science, Pubmed
000062862 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000062862 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000062862 650_2 $$2MeSH$$aAmyloid beta-Peptides: chemical synthesis
000062862 650_2 $$2MeSH$$aAmyloid beta-Peptides: chemistry
000062862 650_2 $$2MeSH$$aHumans
000062862 650_2 $$2MeSH$$aProtein Structure, Quaternary
000062862 650_2 $$2MeSH$$aSensitivity and Specificity
000062862 650_2 $$2MeSH$$aSpectrometry, Fluorescence: methods
000062862 650_7 $$00$$2NLM Chemicals$$aAmyloid beta-Peptides
000062862 650_7 $$2WoSType$$aJ
000062862 7001_ $$0P:(DE-Juel1)VDB65870$$aBirkmann, E.$$b1$$uFZJ
000062862 7001_ $$0P:(DE-HGF)0$$aHenke, F.$$b2
000062862 7001_ $$0P:(DE-HGF)0$$aGörtz, P.$$b3
000062862 7001_ $$0P:(DE-HGF)0$$aLange-Asschenfeldt, C.$$b4
000062862 7001_ $$0P:(DE-HGF)0$$aRiesner, D.$$b5
000062862 7001_ $$0P:(DE-Juel1)132029$$aWillbold, D.$$b6$$uFZJ
000062862 773__ $$0PERI:(DE-600)2155984-3$$a10.1089/rej.2008.0670$$gVol. 11, p. 315 - 318$$p315 - 318$$q11<315 - 318$$tRejuvenation research$$v11$$x1549-1684$$y2008
000062862 8567_ $$uhttp://dx.doi.org/10.1089/rej.2008.0670
000062862 909CO $$ooai:juser.fz-juelich.de:62862$$pVDB
000062862 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000062862 9141_ $$y2008
000062862 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000062862 9201_ $$0I:(DE-Juel1)VDB805$$d31.12.2008$$gINB$$kINB-2$$lMolekulare Biophysik$$x0
000062862 970__ $$aVDB:(DE-Juel1)99745
000062862 980__ $$aVDB
000062862 980__ $$aConvertedRecord
000062862 980__ $$ajournal
000062862 980__ $$aI:(DE-Juel1)ISB-2-20090406
000062862 980__ $$aUNRESTRICTED
000062862 980__ $$aI:(DE-Juel1)ICS-6-20110106
000062862 981__ $$aI:(DE-Juel1)IBI-7-20200312
000062862 981__ $$aI:(DE-Juel1)ISB-2-20090406
000062862 981__ $$aI:(DE-Juel1)ICS-6-20110106